Covance Solution Bridges Preclinical to Clinical Development
Covance Inc., the world’s most comprehensive drug development company, today announced the introduction of Covance Early Phase Development Solutions,
Covance has introduced its Early Phase Development Solutions, a multi-disciplined approach to early drug development that provides sponsors access to a molecule solution team made up of experts from nonclinical, clinical and regulatory disciplines. These experts will focus on the sponsor’s unique target product profile to provide ongoing continuity in strategic program design that spans nonclinical through to first-in-human ready, Phase II ready, proof-of-concept and full-development ready.
Read the full text here.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
FDA Grants Priority Review to Merck’s sBLA for Winrevair After Early Success in ZENITH PAH Trial
July 2nd 2025Merck’s bid to update Winrevair’s label advances with FDA priority review, backed by Phase III ZENITH data showing a 76% reduction in major morbidity and mortality events in patients with pulmonary arterial hypertension.
